The Vox Markets Podcast / Neil Clark, CEO of Destiny Pharma, explains the significance of new data for NTCD-M3, its novel treatment for C. difficile infection

View our embed guidelines

Sorry, your browser isn't supported.

We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.

You can visit our support center if you're having problems.